LARONI, ALICE
LARONI, ALICE
NEUROSCIENZE "RITA LEVI MONTALCINI"
A Real-Life Study of Alemtuzumab: Impact of Previous Therapies and Washout Period on Disease Activity
2018-01-01 Sacca, F; Sormani, MP; Signori, A; Lanzillo, R; Baroncini, D; Annovazzi, P; Signoriello, E; Laroni, A; Capobianco, M; Sartori, A; La Gioia, S; Maniscalco, GT; Cordioli, C; Rasia, S; Clerico, M; Fenu, G; Cocco, E; Frau, J
A real-world study of Alemtuzumab in a cohort of Italian patients
2019-01-01 Sacca, F; Russo, CV; Frau, J; Annovazzi, P; Signoriello, E; Bonavita, S; Grasso, R; Clerico, M; Cordioli, C; Laroni, A; Capobianco, M; Clerici, VT; Sartori, A; Cavalla, P; Maniscalco, GT; La Gioia, S; Caleri, F; Giugno, A; Iodice, R; Carotenuto, A; Cocco, E; Fenu, G; Zaffaroni, M; Baronicini, D; Lus, G; Gallo, A; De Mercanti, SF; Lapucci, C; Di Francescantonio, V; Sormani, MP; Signori, A
Comparative effectiveness of Cladribine tablets vs other drugs in relapsing-remitting multiple sclerosis: an approach merging randomized controlled trial with real life data
2019-01-01 Signori, A; Sacca, F; Lanzillo, R; Maniscalco, GT; Signoriello, E; Repice, A; Annovazzi, P; Baroncini, D; Clerico, M; Binello, E; Cerqua, R; Mataluni, G; Perini, P; Bonavita, S; Lavorgna, L; Zarbo, IR; Laroni, A; Gutierrez, LP; La Gioia, S; Frigeni, B; Barcella, V; Frau, J; Cocco, E; Fenu, G; Clerici, VT; Sartori, A; Rasia, S; Cordioli, C; Stromillo, ML; Di Sapio, A; Pontecorvo, S; Grasso, R; Barone, S; Barrila, C; Russo, CV; Esposito, S; Ippolito, D; Landi, D; Visconti, A; Sormani, MP
Comparative effectiveness of dimethyl fumarate, teriflunomide, interferon-beta and glatiramer acetate on newly diagnosed patients: a propensity score-matched analysis from a multicenter Italian group
2017-01-01 Signori, A; Sormani, MP; Maniscalco, GT; Signoriello, E; Rossi, S; Gutierrez, LP; Sacca, F; Russo, CV; Lo Fermo, S; Repice, AM; Baroncini, D; Annovazzi, P; Clerico, M; Cerqua, R; Binello, E; Mataluni, G; Frau, J; Cocco, E; Zarbo, R; Laroni, A; Sartori, A; Cordioli, C; Rasia, S; Bonavita, S; Lavorgna, L; Esposito, S; Clerici, VALT; La Gioia, S; Frigeni, B; Barcella, V; Pontecorvo, S; Di Sapio, A; Grasso, R; Stromillo, ML; Barrila, C; Gallo, F; Lanzillo, R
Extended interval dosing of natalizumab: is efficacy preserved?
2018-01-01 Clerico, M; Signori, A; De Mercanti, S; Cordioli, C; Signoriello, E; Lus, G; Maniscalco, GT; Curti, E; Lorefice, L; Cocco, E; Nociti, V; Mirabella, M; Baroncini, D; Landi, D; Mataluni, G; Petruzzo, M; Lanzillo, R; Gandoglia, I; Laroni, A; Frangiamore, R; Sartori, A; Cavalla, P; Costantini, G; Sormani, MP; Capra, R
Shift from fingolimod to alemtuzumab: what happens next?
2018-01-01 Frau, J; Sacca, F; Signori, A; Baroncini, D; Fenu, G; Annovazzi, P; Capobianco, M; Signoriello, E; Laroni, A; La Gioia, S; Sartori, A; Maniscalco, GT; Bonavita, S; Clerico, M; Russo, CV; Gallo, A; Lapucci, C; Sormani, MP; Cocco, E
Switching to alemtuzumab from fingolimod or other therapies: impact of wash-out period on disease activity
2017-01-01 Sacca, F; Sormani, MP; Signori, A; Lanzillo, R; Baroncini, D; Annovazzi, P; Signoriello, E; Laroni, A; Capobianco, M; Sartori, A; La Gioia, S; Maniscalco, G; Cordioli, C; Rasia, S; Clerico, M; Cocco, E; Frau, J
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A Real-Life Study of Alemtuzumab: Impact of Previous Therapies and Washout Period on Disease Activity | 2018 | Sacca, F; Sormani, MP; Signori, A; Lanzillo, R; Baroncini, D; Annovazzi, P; Signoriello, E; Laroni, A; Capobianco, M; Sartori, A; La Gioia, S; Maniscalco, GT; Cordioli, C; Rasia, S; Clerico, M; Fenu, G; Cocco, E; Frau, J | |
| A real-world study of Alemtuzumab in a cohort of Italian patients | 2019 | Sacca, F; Russo, CV; Frau, J; Annovazzi, P; Signoriello, E; Bonavita, S; Grasso, R; Clerico, M; Cordioli, C; Laroni, A; Capobianco, M; Clerici, VT; Sartori, A; Cavalla, P; Maniscalco, GT; La Gioia, S; Caleri, F; Giugno, A; Iodice, R; Carotenuto, A; Cocco, E; Fenu, G; Zaffaroni, M; Baronicini, D; Lus, G; Gallo, A; De Mercanti, SF; Lapucci, C; Di Francescantonio, V; Sormani, MP; Signori, A | |
| Comparative effectiveness of Cladribine tablets vs other drugs in relapsing-remitting multiple sclerosis: an approach merging randomized controlled trial with real life data | 2019 | Signori, A; Sacca, F; Lanzillo, R; Maniscalco, GT; Signoriello, E; Repice, A; Annovazzi, P; Baroncini, D; Clerico, M; Binello, E; Cerqua, R; Mataluni, G; Perini, P; Bonavita, S; Lavorgna, L; Zarbo, IR; Laroni, A; Gutierrez, LP; La Gioia, S; Frigeni, B; Barcella, V; Frau, J; Cocco, E; Fenu, G; Clerici, VT; Sartori, A; Rasia, S; Cordioli, C; Stromillo, ML; Di Sapio, A; Pontecorvo, S; Grasso, R; Barone, S; Barrila, C; Russo, CV; Esposito, S; Ippolito, D; Landi, D; Visconti, A; Sormani, MP | |
| Comparative effectiveness of dimethyl fumarate, teriflunomide, interferon-beta and glatiramer acetate on newly diagnosed patients: a propensity score-matched analysis from a multicenter Italian group | 2017 | Signori, A; Sormani, MP; Maniscalco, GT; Signoriello, E; Rossi, S; Gutierrez, LP; Sacca, F; Russo, CV; Lo Fermo, S; Repice, AM; Baroncini, D; Annovazzi, P; Clerico, M; Cerqua, R; Binello, E; Mataluni, G; Frau, J; Cocco, E; Zarbo, R; Laroni, A; Sartori, A; Cordioli, C; Rasia, S; Bonavita, S; Lavorgna, L; Esposito, S; Clerici, VALT; La Gioia, S; Frigeni, B; Barcella, V; Pontecorvo, S; Di Sapio, A; Grasso, R; Stromillo, ML; Barrila, C; Gallo, F; Lanzillo, R | |
| Extended interval dosing of natalizumab: is efficacy preserved? | 2018 | Clerico, M; Signori, A; De Mercanti, S; Cordioli, C; Signoriello, E; Lus, G; Maniscalco, GT; Curti, E; Lorefice, L; Cocco, E; Nociti, V; Mirabella, M; Baroncini, D; Landi, D; Mataluni, G; Petruzzo, M; Lanzillo, R; Gandoglia, I; Laroni, A; Frangiamore, R; Sartori, A; Cavalla, P; Costantini, G; Sormani, MP; Capra, R | |
| Shift from fingolimod to alemtuzumab: what happens next? | 2018 | Frau, J; Sacca, F; Signori, A; Baroncini, D; Fenu, G; Annovazzi, P; Capobianco, M; Signoriello, E; Laroni, A; La Gioia, S; Sartori, A; Maniscalco, GT; Bonavita, S; Clerico, M; Russo, CV; Gallo, A; Lapucci, C; Sormani, MP; Cocco, E | |
| Switching to alemtuzumab from fingolimod or other therapies: impact of wash-out period on disease activity | 2017 | Sacca, F; Sormani, MP; Signori, A; Lanzillo, R; Baroncini, D; Annovazzi, P; Signoriello, E; Laroni, A; Capobianco, M; Sartori, A; La Gioia, S; Maniscalco, G; Cordioli, C; Rasia, S; Clerico, M; Cocco, E; Frau, J |